Skip to content

In the BioHarmony Drug Report Database

Lusutrombopag

Mulpleta, Lusutrombopag Shionogi, Mulpleo (lusutrombopag) is a small molecule pharmaceutical. Lusutrombopag was first approved as Mulpleta on 2018-07-31. It is used to treat thrombocytopenia in the USA. It has been approved in Europe to treat thrombocytopenia. The pharmaceutical is active against thrombopoietin receptor. Mulpleta's patents are valid until 2031-09-29 (FDA).
Trade Name Lusutrombopag Shionogi, Mulpleo
Common Name Lusutrombopag
Indication thrombocytopenia
Drug Class Thrombopoetin agonists
Lusutrombopag
Get full access now